Full-Time
Updated on 9/10/2026
Biopharmaceuticals focused on neuroscience and oncology
$160k - $240k/yr
Vermont, USA + 6 more
More locations: Connecticut, USA | New Hampshire, USA | Rhode Island, USA | New York, NY, USA | Maine, USA | Massachusetts, USA
Remote
Remote within the listed states; requires approximately 60% travel and proximity to a major airport.
Master's, PharmD, PhD, MD
See people who can refer or advise you
Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Dublin, Ireland
Founded
2003
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.
Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.
Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.
Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.
Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.